The Bethesda System for Reporting Thyroid Cytopathology, Laila Khazai 11/4/17
|
|
- Scot Baker
- 6 years ago
- Views:
Transcription
1 The Bethesda System for Reporting Thyroid Cytopathology, 2017 Laila Khazai 11/4/17
2 In Summary No major changes for cytologists. The clinical team is faced with different risk of malignancies (ROM) associated with for Bethesda categories III to VI, especially III and IV (NIFTP constitutes a substantial proportion of the malignancies hidden in these categories).
3
4
5 Non-diagnostic/Unsatisfactory Bethesda Category I
6 I & II Any sample with significant cytologic atypia is adequate (a minimum number of follicular cells is not required). Any sample with abundant colloid is adequate and benign. Nodules in patients with lymphocytic thyroiditis, abscess, or granulomatous thyroiditis do not need a minimum number of follicular cells. Preliminary data suggest that requiring a smaller number of follicular cells would significantly reduce ND interpretations without significantly reducing the falsenegative rate.
7 Benign Follicular Nodule Bethesda Category I
8
9
10
11 Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Bethesda Category III
12 III The provisional goal of limiting AUS/FLUS interpretations to 7% of all thyroid FNA interpretations is increased to 10%. The AUS/FLUS to malignant ratio may be a useful laboratory quality measure that should not exceed 3.0. Narrative comments are strongly recommended to further describe the findings, especially if it would potentially influence management. The possibility of a compromised sample with artifactual changes should be acknowledged in the report.
13 Atypia Cytologic Architectural Cytologic and architectural Hurthle cell aspirates Atypia, NOS
14 Cytologic Atypia
15 Cytologic Atypia
16 Architectural Atypia
17 Cytologic & Architectural atypia
18 Hurthle-cell Aspirates
19 Atypia, NOS
20 III AUS/FLUS aspirates with cytologic (nuclear) atypia have an approximately twofold higher risk of malignancy (ROM) compared with cases with architectural atypia. Rare pseudoinclusions by themselves may prompt an AUS/FLUS diagnosis, but if accompanied by other compelling features of PTC, the case should be considered suspicious for malignancy.
21 III Hurthle cell type AUS/FLUS has a lower ROM than other atypical patterns. Considering the rarity of Hurthle cell carcinoma in a background of lymphocytic thyroiditis, cases with obvious Hashimoto thyroiditis and an atypical collection of Hurthle cells should typically be diagnosed as benign. It is acceptable to diagnose a moderately to markedly cellular sample composed exclusively of Hurthle cells yet the clinical setting suggests a benign Hurthle cell nodule, such as lymphocytic thyroiditis or a multinodular goiter, as AUS/FLUS.
22 LT
23 MNG
24 III With the introduction of NIFTP entity, early data suggests that the ROM for this category may be reduced by as much as 45%. Aspirates with a pattern highly associated with the follicular variant of PTC/NIFTP (diffuse but subtle nuclear enlargement, focal nuclear irregularity, only occasional nuclear grooves, and a microfollicular architecture) are better classified as suspicious for malignancy when nuclear alterations are prominent, or suspicious for a follicular neoplasm when microfollicular architecture is more pronounced.
25 Follicular Neoplasm/Suspicious for a Follicular Neoplasm Bethesda Category IV
26 IV Each lab should choose the name it prefers and use it exclusively for that category. The goal of this category is to identify all potential follicular carcinomas. Follicular-patterned aspirates with mild nuclear changes can be classified as FN/SFN so long as true papillae and intra-nuclear pseudoinclusions are absent.
27 IV Although FNA is highly sensitive for detecting oncocytic carcinomas, its specificity is low; most nodules diagnosed as FNHCT/SFNHCT are benign (ROM : 10-40%). It is advisable to use the guidelines of the WHO, which consider only those follicular neoplasms that are composed of >75% Hurthle cells to be a Hurthle-cell neoplasm. With lower percentages, a practical solution is to diagnose those aspirates as FN/SFN, with a comment that there is some Hurthle cell differentiation, and therefore, a Hurthle cell neoplasm can not be ruled out.
28 IV The criteria for FNHCT/SFNHCT have lower predictive value for malignancy when a patient has lymphocytic thyroiditis or multinodular goiter. It is acceptable to interpret as AUS/FLUS, with a note explaining that benign Hurthle-cell hyperplasia is favored. The goal is to provide the clinical team with the opportunity to avoid an unnecessary lobectomy in some of these patients.
29 Suspicious for Malignancy Bethesda Category V
30 V Most FVPTCs/NIFTPs are diagnosed cytologically as either SFM (25-35%), FN/SFN (25-30%), or AUS/FLUS (10-20%). The malignancy risk of the SFM category falls to approximately 50% (range 45-60%) when NIFTPs are not counted as malignant. It remains to be seen whether any collection of cytologic features is sufficiently reliable to allow prospective identification of NIFTP and its distinction from an invasive FVPTC by FNA alone.
31 V ATA initiatives to reduce the extent of surgery for many low-risk thyroid cancers (4 cm or smaller, without extra-thyroidal extension and lacking regional nodal metastasis) and decreased routine use of postoperative radioactive iodine treatment increasingly raise the possibility for lobectomy as initial surgical management. The exact clinical and surgical impact of re-classification of NIFTP is yet to be determined, but clearly will help push the pendulum toward consideration of a more conservative initial surgical procedure in many circumstances.
32 V The ultimate goal of separating a suspicious from malignant category is to preserve the very high PPV of the malignant category without compromising the overall sensitivity of FNA.
33 Malignant Bethesda Category VI
34 VI NIFTP comprises approximately 20-25% of all thyroid tumors previously classified as malignant. Taking into consideration the reclassification of some PTCs as NIFTP, when a definitive diagnosis of PTC is made by FNA, 94-96% prove to be PTC on histologic follow-up (drop from previous 99% PPV). It is desirable to eliminate tumors likely to represent NIFTP.
35 VI Preliminary data suggest that a definitive ( malignant ) diagnosis if PTC should be reserved for cases that have, in addition to other characteristic features, at least one of the following: papillary architecture, psammoma bodies, and INCIs. A suspected PTC with an exclusively follicular architecture, especially one that lacks such features (e.g. many follicular variants of PTC), is best interpreted as suspicious for malignancy rather than malignant.
36 VI Nevertheless, given the histologic criteria for NIFTP, it is unlikely that NIFTPs can be completely eliminated form the malignant category.
37 Overview of Commonly Used Molecular Tests
38
39 AFIRMA Gene Expression Classifier Microarray technology used to analyze the mrna expression of 167 genes (the selected gene profile is based on the gene expression identified from FNAs of surgically proven benign and malignant thyroid nodules). Only AUS/FLUS and FN/SFN- SFNTCT/FNHCT cases are accepted. Needs two dedicated passes, in a nucleic acid preservative solution. Reported as benign or suspicious. Can pickup parathyroid origin.
40 AMCs Later on, Veracyte introduced the Afirma Malignancy Classifiers (AMCs) to further enhance the test as a comprehensive diagnostic tool to assess the risk of malignancy including medullary thyroid carcinoma. Include an mrna profile for medullary carcinoma and/or BRAF V600E gene mutation. Only performed on FNA samples carrying a suspicious and malignant cytomorphologic diagnosis, or a suspicious AFIRMA GEC result.
41 AFIRMA High negative predictive value (NPV) for nodules in the AUS/FLUS and FN/SFN categories (almost equal to the NPV of an FNA morphologically diagnosed as benign); rule out test. Then NPV in FNAs morphologically diagnosed as suspicious for malignancy is much lower. Low positive predictive value (PPV) for nodules in the AUS/FLUS and FN/SFN categories. Tendency to report a high percentage of benign Hurthle-cell nodules as suspicious.
42 Thyroseq Test Next generation sequencing (NGC) based mutation and fusion panel initially designed to target 12 cancer genes and 284 mutational hot spots. The enhanced version (Thyroseq v2) includes a more extensive panel of DNA alterations (14 genes, including >1000 mutations) and RNA alterations (42 fusions, 16 genes for expression). Only AUS/FLUS and FN/SFN- SFNTCT/FNHCT are accepted. Needs 1-2 drops from the first pass if adequate cellularity on, stored at -20. Reported as specific gene mutation/translocation. Can pickup parathyroid origin.
43 Thyroseq High positive predictive value (PPV); rule in test. Low negative predictive value (NPV). The new version (v2) has been claimed to have improved NPV, enough to potentially function as a rule out test as well (the exception would be a population with a very high pre-test probability of malignancy). Potential increased chance of detecting false-positive molecular abnormalities associated with the expanded NGS-based mutational profile; i.e. lower PPV compared to the original version.
44 Important To Remember While sensitivity and specificity are intrinsic characteristics, the PPV and NPV of any test depends on the prevalence of disease in the tested population/practice setting. The PPVs are expected to decrease for all currently available molecular tests, as NIFTP was considered a malignant neoplasm in the validation studies and subsequent studies.
45 Current ATA Guidelines The molecular testing should be performed in a CLIA/CAP- certified molecular laboratory, or international equivalent. There is currently no single optimal molecular test that can definitely rule in or rule out malignancy in all cases of indeterminate cytology, and longterm outcome data providing clinical utility are required.
46 Current ATA Guidelines For nodules with AUS/FLUS cytology, after consideration of clinical and sonographic features, investigations such as repeat FNA or molecular testing may be used to supplement malignancy risk assessment in lieu of proceeding directly with a strategy of either surveillance or diagnostic surgery. For nodules with FN/SFN cytology, after consideration of clinical and sonographic features, molecular testing may be used to supplement malignancy risk assessment data in lieu of proceeding directly with surgery.
47 Thank You
THYROID CYTOLOGY THYROID CYTOLOGY FINE-NEEDLE-ASPIRATION ANCILLARY TESTS IN THYROID FNA
ANCILLARY TESTS IN THYROID FNA Prof. Fernando Schmitt Department of Pathology and Oncology, Medical Faculty of Porto University Head of Molecular Pathology Unit, IPATIMUP General-Secretary of the International
More informationNIFTP Cytologic Aspects
NIFTP Cytologic Aspects William C. Faquin, MD PhD Director, Head and Neck Pathology Massachusetts General Hospital & Massachusetts Eye and Ear Infirmary Boston, MA USA So, what is the story about FVPTC
More informationBuilding On The Best A Review and Update on Bethesda Thyroid 2017
Building On The Best A Review and Update on Bethesda Thyroid 2017 Syed Z. Ali, MD, FRCPath, FIAC Professor of Pathology and Radiology The Johns Hopkins Hospital, Baltimore, Maryland USA TBSRTC Diagnostic
More informationThyroid Nodules: Understanding FNA Cytology (The Bethesda System for Reporting of Thyroid Cytopathology) Shamlal Mangray, MB, BS
Thyroid Nodules: Understanding FNA Cytology (The Bethesda System for Reporting of Thyroid Cytopathology) Shamlal Mangray, MB, BS Attending Pathologist Rhode Island Hospital, Providence, RI DISCLOSURE:
More informationTBSRTC 1- Probabilistic approach and Relationship to Clinical Algorithms
The Benefits of a Uniform Reporting System for Thyroid Cytopathology BETHESDA REPORTING SYSTEM Prof. Fernando Schmitt Department of Pathology and Oncology, Medical Faculty of Porto University Head of Molecular
More informationThe Bethesda Indeterminate Categories: An Update to Diagnosis and Molecular Testing
William C. Faquin, MD, PhD Professor of Pathology Harvard Medical School Director, Head and Neck Pathology Massachusetts Eye and Ear Massachusetts General Hospital The Bethesda Indeterminate Categories:
More information3/22/2017. Disclosure of Relevant Financial Relationships. Cytomorphologic Thresholds for Classifying Thyroid FNAs as Suspicious and Positive for PTC
Cytomorphologic Thresholds for Classifying Thyroid FNAs as Suspicious and Positive for PTC Tarik M. Elsheikh, MD Professor and Medical Director Anatomic Pathology Cleveland Clinic Laboratories Disclosure
More informationCytomorphologic Thresholds for Classifying Thyroid FNAs as Suspicious and Positive for PTC
Cytomorphologic Thresholds for Classifying Thyroid FNAs as Suspicious and Positive for PTC Tarik M. Elsheikh, MD Professor and Medical Director Anatomic Pathology Cleveland Clinic Laboratories Case Study
More information2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines
2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines Angela M. Leung, MD, MSc, ECNU November 5, 2016 Outline Workup of nontoxic thyroid nodule(s) Ultrasound FNAB Management of FNAB results
More informationBackground to the Thyroid Nodule
William C. Faquin, MD, PhD Professor of Pathology Harvard Medical School Director of Head and Neck Pathology Massachusetts Eye and Ear Massachusetts General Hospital THYROID FNA: PART I Background to the
More information3/27/2017. Disclosure of Relevant Financial Relationships. Each year over 550,000 thyroid FNAs are performed in the U.S.!!! THYROID FNA: THE GOOD NEWS
Disclosure of Relevant Financial Relationships William C. Faquin, MD, PhD Director, Head and Neck Pathology Massachusetts Eye and Ear Massachusetts General Hospital Professor of Pathology Harvard Medical
More information"Atypical": Criteria and
"Atypical": Criteria and Controversies Esther Rossi MD PhD MIAC Division of Anatomic Pathology and Cytology Catholic University of Sacred Heart Rome, Italy CASE HISTORY In 2015, 45 y/o woman underwent
More informationASC Companion Meeting at the 2017 USCAP: Ancillary Molecular Testing in "Indeterminate. Thyroid Nodules: How Far Have We Come?
ASC Companion Meeting at the 2017 USCAP: Ancillary Molecular Testing in "Indeterminate Thyroid Nodules: How Far Have We Come? William C. Faquin, MD, PhD, Massachusetts General Hospital, Boston, MA The
More informationThe Frozen Section: Diagnostic Challenges and Pitfalls
The Frozen Section: Diagnostic Challenges and Pitfalls William C. Faquin, M.D., Ph.D. Director, Head and Neck Pathology Massachusetts General Hospital & Massachusetts Eye and Ear Infirmary Harvard Medical
More informationDilemmas in Cytopathology and Histopathology
Dilemmas in Cytopathology and Histopathology Yuri E. Nikiforov, MD, PhD Division of Molecular & Genomic Pathology University of Pittsburgh Medical Center, USA Objectives Discuss new WHO classification
More informationThyroid FNA: Diagnosis, Challenges and Solutions. Disclosures
Thyroid FNA: Diagnosis, Challenges and Solutions Zubair W. Baloch, MD, PhD None Disclosures 1 Questions to Myself? Where We are Now? The Present 2 Reality Check There is More to How Thyroid Nodules are
More informationThyroid follicular neoplasms in cytology. Ulrika Klopčič Institute of Oncology, Department of Cytopathology, Ljubljana, Slovenia
Thyroid follicular neoplasms in cytology Ulrika Klopčič Institute of Oncology, Department of Cytopathology, Ljubljana, Slovenia Lecture overview importance of FNAB in assessing thyroid lesions follicular
More informationCase #1 FNA of nodule in left lobe of thyroid in 67 y.o. woman
Challenging Cases Manon Auger M.D., F.R.C.P. (C) Professor, Department of Pathology McGill University Director, Cytopathology Laboratory McGill University it Health Center Case #1 FNA of nodule in left
More information5/3/2017. Ahn et al N Engl J Med 2014; 371
Alan Failor, M.D. Clinical Professor of Medicine Division of Metabolism, Endocrinology and Nutrition University of Washington April 20, 2017 No disclosures to report 1. Appropriately evaluate s in adult
More informationMolecular Testing for Indeterminate Thyroid Nodules. October 20, 2018
Molecular Testing for Indeterminate Thyroid Nodules October 20, 2018 Patient 1: Left 1.0 cm AP x 1.6 cm transverse x 2.1 cm in length Well defined Isoechoic heterogeneous No calcification Grade 3 Vascularity
More informationCN 925/15 History. Microscopic Findings
CN 925/15 History 78 year old female. FNA indeterminate lesion right thyroid lobe. Previous THY1C (UK) Bethesda category 1 cyst fluid. Ultrasound showed part solid/cystic changes, indeterminate in nature
More informationThyroid master class. Thyroid Fine needle aspiration cytology and liquid-based techniques: Hologic and Becton Dickinson
Thyroid master class Thyroid Fine needle aspiration cytology and liquid-based techniques: Hologic and Becton Dickinson Principle of LBC Collection of cells in liquid medium Immediate fixation Processor-prepared
More informationLet s Make Sense of Present & Predict Future. In Light of Past 1/12/2016
The New Diagnostic Paradigms in Thyroid Surgical Pathology and Affects on Reporting of Thyroid Fine Needle Aspiration Specimens Deliberations, Criticisms & Discussions Zubair W. Baloch, MD, PhD. Professor
More informationXIII CONGRESSO NAZIONALE Roma, 7-9 novembre NODULO TIROIDEO: Agoaspirato o Core Needle Biopsy?
XIII CONGRESSO NAZIONALE NODULO TIROIDEO: Agoaspirato o Core Needle Biopsy? Anna Crescenzi Policlinico Universitario Campus Bio-Medico Roma Indeterminate lesions are heterogeneous The gray zone CONSERVATIVE
More informationACCME/Disclosures. Questions to Myself? 4/11/2016
The New Diagnostic Paradigms in Thyroid Surgical Pathology and Affects on Reporting of Thyroid Fine-Needle Aspiration Specimens Deliberations, Criticisms & Discussions Zubair W. Baloch, MD, PhD. Professor
More informationFNA of Thyroid. Toward a Uniform Terminology With Management Guidelines. NCI NCI Thyroid FNA State of the Science Conference
FNA of Thyroid NCI NCI Thyroid FNA State of the Science Conference Toward a Uniform Terminology With Management Guidelines Thyroid Thyroid FNA Cytomorphology NCI Thyroid FNA State of the Science Conference
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Molecular Markers for Fine Needle Aspirates of Thyroid Nodules MP-065-MD-DE Medical Management Provider Notice Date: 10/15/2018;
More informationAmerican Society of Cytopathology Companion Society Symposium Uses and Misuses of Ancillary Tests in Cytopathology
American Society of Cytopathology Companion Society Symposium Uses and Misuses of Ancillary Tests in Cytopathology Zubair W. Baloch. MD, PhD. Professor of Pathology, UPENN Medical Center Perelman School
More informationThyroid Nodules. No conflicts. Overview 5/16/2017. UCSF Internal Medicine Updates May 22, 2017 Elizabeth Murphy, MD, DPhil
Thyroid Nodules UCSF Internal Medicine Updates May 22, 2017 Elizabeth Murphy, MD, DPhil No conflicts Overview Thyroid nodule and cancer review Ultrasound FNA cytology Nodule follow up Putting it all together
More informationCytology for the Endocrinologist. Nicole Massoll M.D
Cytology for the Endocrinologist Nicole Massoll M.D Objectives Discuss slide preperation Definitions of adequacy ROSE (Rapid On-Site Evaluation) Thyroid Cytology Adequacy Nicole Massoll M.D. University
More informationUpdate on Thyroid FNA The Bethesda System. Shikha Bose M.D. Associate Professor Cedars Sinai Medical Center
Update on Thyroid FNA The Bethesda System Shikha Bose M.D. Associate Professor Cedars Sinai Medical Center Thyroid Nodules Frequent occurrence Palpable: 4-7% of adults Ultrasound: 10-31% Majority benign
More informationThyroid Cytopathology: What s New and What s Old That We Don t All Agree on?
Thyroid Cytopathology: What s New and What s Old That We Don t All Agree on? RITU NAYAR, MD PROFESSOR & VICE CHAIR OF PATHOLOGY NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE DIRECTOR OF CYTOPATHOLOGY,
More informationThyroid Cytopathology: Weighing In The Bethesda System
Thyroid Cytopathology: Weighing In The Bethesda System V8 Conflicts No financial consideration Bias Work in the Canadian environment where litigation is less Thyroid cytology is often referred in by small
More informationEvaluation and Management of Thyroid Nodules. Nick Vernetti, MD, FACE Palm Medical Group Las Vegas, Nevada
Evaluation and Management of Thyroid Nodules Nick Vernetti, MD, FACE Palm Medical Group Las Vegas, Nevada Disclosure Consulting Amgen Speaking Amgen Objectives Understand the significance of incidental
More informationImproving the Long Term Management of Benign Thyroid Nodules
25 th Annual Scientific AACE Clinical Congress Improving the Long Term Management of Benign Thyroid Nodules Stephanie L. Lee, MD, PhD Director, Thyroid Health Center Section of Endocrinology, Diabetes
More informationNCI Thyroid FNA State of the Science Conference. The Bethesda System For Reporting Thyroid Cytopathology
The Bethesda System For Reporting Thyroid Cytopathology Towards a Uniform Terminology With Management Guidelines NCI Thyroid FNA State of the Science Conference Bethesda, MD October 22-23, 2007 154 registrants
More informationDOWNLOAD ENTIRE DOCUMENT FROM
PREVIEW ONLY 1 Atlas on Bethesda system for reporting Thyroid Cytology PREVIEW ONLY 2 OVERVIEW 1. Indications and goal of thyroid FNA 2. Contraindications 3. Procurement of cell sample 4. Staining methods
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid
Medical Policy Manual Genetic Testing, Policy No. 49 Molecular Markers in Fine Needle Aspirates of the Thyroid Next Review: April 2019 Last Review: June 2018 Effective: July 1, 2018 IMPORTANT REMINDER
More informationRelationship of Cytological with Histopathological Examination of Palpable Thyroid Nodule
Relationship of Cytological with Histopathological Examination of Palpable Thyroid Nodule NAUSHEEN HENNA 1, SHAHZAD AHMED FAKHAR 2, NAVEED AKHTER 3, MUHAMMAD MASOOD AFZAL 4, KHIZER AFTAB AHMAD KHAN 5,
More informationTHE FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA AND NIFTP
THE FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA AND NIFTP FOLLICULAR VARIANT OF PAPILLARY CARCINOMA HISTORICAL PERSPECTIVE FOLLICULAR VARIANT OF PAPILLARY CARCINOMA 1960 described by Dr. Stuart Lindsay
More informationMarkers in Thyroid Nodule Evaluation. Yuri E. Nikiforov, MD, PhD Division of Molecular & Genomic Pathology University of Pittsburgh Medical Center
Markers in Thyroid Nodule Evaluation Yuri E. Nikiforov, MD, PhD Division of Molecular & Genomic Pathology University of Pittsburgh Medical Center Disclosures Quest Diagnostics (consultant) UPMC/CBLPath
More informationSection 2 Original Policy Date 2013 Last Review Status/Date September 1, 2014
Policy Number 2.04.82 Molecular Markers in Fine Needle Aspirates of the Thyroid Medical Policy Section 2 Original Policy Date 2013 Last Review Status/Date September 1, 2014 Disclaimer Our medical policies
More informationAn Alphabet Soup of Thyroid Neoplasms
Overall Objectives An Alphabet Soup of Thyroid Neoplasms Lester D. R. Thompson www.lester-thompson.com What is the current management of papillary carcinoma? What are the trends and what can we do differently?
More informationNIFTP: Histopathology of a Cytological Monkey Wrench. B. Wehrli
NIFTP: Histopathology of a Cytological Monkey Wrench B. Wehrli Non-Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma Before 2016 Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like
More informationUltrasound-Guided Fine-Needle Aspiration of Thyroid Nodules: New events
Ultrasound-Guided Fine-Needle Aspiration of Thyroid Nodules: New events Sandrine Rorive, M.D., PhD. Erasme Hospital - Université Libre de Bruxelles (ULB) INTRODUCTION The assessment of thyroid nodules
More informationFine-needle aspiration (FNA) cytology plays an important
Update on Molecular Testing for Cytologically Indeterminate Thyroid Nodules Michiya Nishino, MD, PhD; Marina Nikiforova, MD Context. Approximately 15% to 30% of thyroid nodules that undergo fine-needle
More informationPathology of the Thyroid
Pathology of the Thyroid Thyroid Carcinoma Arising from Follicular Cells 2015-01-19 Prof. Dr. med. Katharina Glatz Pathologie Carcinomas Arising from Follicular Cells Differentiated Carcinoma Papillary
More informationInter-observer reproducibility using The Besthesda System for Reporting Thyroid Cytopathology (TBSRTC)
SHORT COMMUNICATION Inter-observer reproducibility in thyroid cytology reporting Inter-observer reproducibility using The Besthesda System for Reporting Thyroid Cytopathology (TBSRTC) Doshi Neena 1*, Jhabuawala
More informationThyroid Neoplasm. ORL-Head and neck Surgery 2014
In The Name of God Thyroid Neoplasm ORL-Head and neck Surgery 2014 Malignant Neoplasm By age 90, virtually everyone has nodules Estimates of cancer prevalence at autopsy 4% to 36% Why these lesions are
More informationDr Catherine Woolnough, Hospital Scientist, Chemical Pathology, Royal Prince Alfred Hospital. NSW Health Pathology University of Sydney
Dr Catherine Woolnough, Hospital Scientist, Chemical Pathology, Royal Prince Alfred Hospital NSW Health Pathology University of Sydney Thyroid Cancer TC incidence rates in NSW Several subtypes - Papillary
More informationJournal of Diagnostic Pathology 2011 (6); 1: Leading Article
Leading Article Beyond the horizon of current thyroid cytology reporting in Sri Lanka... Lokuhetty MDS Thyroid enlargement is a commonly encountered clinical problem among Sri Lankan patients, be it diffuse
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Molecular Markers in Fine Needle Aspirates of the Thyroid Page 1 of 40 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Molecular Markers in Fine Needle Aspirates
More informationDIAGNOSIS AND REPORTING OF FOLLICULAR-PATTERNED THYROID LESIONS BY FINE NEEDLE ASPIRATION
Follicular-patterned thyroid lesions, WC Faquin 1 DIAGNOSIS AND REPORTING OF FOLLICULAR-PATTERNED THYROID LESIONS BY FINE NEEDLE ASPIRATION William C. Faquin, M.D., Ph.D Department of Pathology, Massachusetts
More informationFollicular Derived Thyroid Tumors
Follicular Derived Thyroid Tumors Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University of Arkansas for Medical Sciences
More informationIntroduction 10/27/2011. Follicular Lesion/Atypia of Undetermined Significance
Follicular Lesion/Atypia of Undetermined Significance Tarik M. Elsheikh, MD Cleveland Clinic Cleveland, Ohio Diagnostic Categories Proposed by Bethesda System/NCI Thyroid Conference 1. Benign 2. Follicular
More information04/09/2018. Follicular Thyroid Tumors Updates in Classification & Practical Tips. Dissecting Indeterminants. In pursuit of the low grade malignancy
Follicular Thyroid Tumors Updates in Classification & Practical Tips Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University
More informationVolume 2 Issue ISSN
Volume 2 Issue 3 2012 ISSN 2250-0359 Correlation of fine needle aspiration and final histopathology in thyroid disease: a series of 702 patients managed in an endocrine surgical unit *Chandrasekaran Maharajan
More informationMedical Policy. Title: Genetic Testing- Molecular Markers in Fine Needle Aspirates (FNA) of the Thyroid
Medical Policy Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate
More informationNoninvasive follicular thyroid neoplasm with papillary-like nuclear features: a single-institutional experience in Japan
2017, 64 (12), 1149-1155 Original Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a single-institutional experience in Japan Mitsuyoshi Hirokawa 1), Miyoko Higuchi 2), Ayana
More informationKyle C. Strickland, MD, PhD; Brooke E. Howitt, MD; Justine A. Barletta, MD; Edmund S. Cibas, MD Jeffrey F. Krane, MD, PhD
Suggesting the Cytologic Diagnosis of Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features (NIFTP): A Retrospective Analysis of Atypical and Suspicious Nodules Kyle C. Strickland,
More informationNew entities in thyroid pathology: update according to the WHO classification
New entities in thyroid pathology: update according to the WHO classification R.R. de Krijger, Dept. of Pathology, University Medical Center and Princess Maxima Center, Utrecht, The Netherlands New issues
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Molecular Markers in Fine Needle Aspirates of the Thyroid Page 1 of 25 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Molecular Markers in Fine Needle Aspirates
More informationManagement of Thyroid Nodules. February 2 nd, 2018 Sarah Hopkins
Management of Thyroid Nodules February 2 nd, 2018 Sarah Hopkins No disclosures Goals: Review Initial Evaluation of Thyroid Nodules Review Indications for Biopsy Approach to Multinodular Goiter Review Management
More informationCorrespondence should be addressed to David N. Bimston; Received 23 January 2017; Accepted 20 March 2017; Published 13 April 2017
Hindawi International Surgical Oncology Volume 2017, Article ID 4689465, 6 pages https://doi.org/10.1155/2017/4689465 Research Article Noninvasive Encapsulated Follicular Variant of Papillary Thyroid Cancer:
More informationHEAD AND NECK ENDOCRINE SURGERY
HEAD AND NECK ENDOCRINE SURGERY OCTOBER 22-23, 2010 THE MARK HOPKINS SAN FRANCISCO, CA THYROID FNA AND CYTOPATHOLOGY THEODORE R. MILLER, MD THE THYROID NODULE Prevalence of palpable nodule: Female ~ 6%
More informationHow to Handle Thyroid FNA
How to Handle Thyroid FNA Maoxin Wu, MD, PhD Chief of Cytopathology Director of Fine Needle Aspiration (FNA) and Core Biopsy Services Clinical Professor, Department of Pathology Joint appointment, Department
More informationSURGICAL UTILITY OF AFIRMA: EFFECTS OF HIGH CANCER PREVALENCE AND ONCOCYTIC CELL TYPES IN PATIENTS WITH INDETERMINATE THYROID CYTOLOGY
ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited, typeset
More informationEvaluation and Management of Thyroid Nodules. Overview of Thyroid Nodules and Their Management. Thyroid Nodule detection: U/S versus Exam
Overview of Thyroid Nodules and Their Management Matthew D. Ringel, M.D. Professor of Medicine Divisions of Endocrinology and Oncology, The Ohio State University Co-Director, Thyroid Cancer Unit Arthur
More informationHow to Use Molecular Genetic Studies in Endocrine Disease? (in the Management of Well- Differentiated Thyroid Cancer) No Conflicts to Declare
How to Use Molecular Genetic Studies in Endocrine Disease? (in the Management of Well- Differentiated Thyroid Cancer) No Conflicts to Declare Quan-Yang Duh Professor of Surgery University of California,
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid
Molecular Markers in Fine Needle Aspirates of the Thyroid Policy Number: 2.04.78 Last Review: 3/2018 Origination: 3/2013 Next Review: 3/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid
Molecular Markers in Fine Needle Aspirates of the Thyroid Policy Number: 2.04.78 Last Review: 9/2018 Origination: 3/2013 Next Review: 3/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationThyroid Nodule. Disclosure. Learning Objectives P A P A P A 3/18/2014. Nothing to disclose.
Thyroid Nodule Evaluating the patient with a thyroid nodule and some management options. Miguel V. Valdez PA C Disclosure Nothing to disclose. Learning Objectives Examination of thyroid gland Options for
More informationPotential Pitfalls for False Suspicion of Papillary Thyroid Carcinoma:
SUPPLEMENT 1 SPECIAL ISSUE: CYTOPATHOLOGY OF THE THYROID GLAND Guest Editor: Zubair Baloch Potential Pitfalls for False Suspicion of Papillary Thyroid Carcinoma: A Cytohistologic Review of 22 Cases Xin
More informationUPDATE ON THE Bethesda system for reporting thyroid cytology
UPDATE ON THE Bethesda system for reporting thyroid cytology Esther Rossi MD PhD MIAC Division of Anatomic Pathology and Cytology Catholic University of Sacred Heart Rome, Italy Present < Current State
More information4/22/2010. Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey.
Management of Differentiated Thyroid Cancer: Head Neck Surgeon Perspective Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey Thyroid gland Small endocrine gland:
More informationTHE BETHESDA SYSTEM FOR REPORTING THYROID CYTOPATHOLOGY: A TWO YEAR INSTITUTIONAL AUDIT
IJCRR Section: Healthcare Sci. Journal Impact Factor 4.016 Research Article THE BETHESDA SYSTEM FOR REPORTING THYROID CYTOPATHOLOGY: A TWO YEAR INSTITUTIONAL AUDIT Salma Bhat 1, Nazia Bhat 1, Humaira Bashir
More information8 Classifying Your Thyroid FNA Specimens Using Bethesda Terminology: Use of Adjunct Molecular Reflex Testing
8 Classifying Your Thyroid FNA Specimens Using Bethesda Terminology: Use of Adjunct Molecular Reflex Testing Constantine Theoharis MD, FASCP David Chhieng MD, FASCP 2011 Annual Meeting Las Vegas, NV AMERICAN
More informationCase #1. Ed Stelow, MD University of Virginia
Case #1 Ed Stelow, MD University of Virginia Imagine, If You Will It s 4:30 on Friday Last cytology case A thyroid FNA from outside that did not have any onsite interpretation It is from a 45-year old
More information9/6/2016 DISCLOSURES. None to disclose. The Present WHERE WE ARE NOW?
9/6/2016 SESSION #3000 CHANGING PARADIGMS IN THE DIAGNOSIS OF ENCAPSULATED FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA DELIBERATIONS, DISCUSSIONS AND CONTROVERSIES. Virginia A. LiVolsi, Raja R. Seethala
More informationOverview of Indeterminate Cytology
83 rd Annual Meeting American Thyroid Association Overview of Indeterminate Cytology Scott Boerner MD FRCPC Head Cytopathology, University Health Network University of Toronto DISCLOSURE Nothing to disclose
More informationRelated Policies None
Medical Policy MP 2.04.78 BCBSA Ref. Policy: 2.04.78 Last Review: 12/27/2017 Effective Date: 03/01/2018 Section: Medicine End Date: 09/27/2018 Related Policies None DISCLAIMER Our medical policies are
More informationAACE Thyroid Cancer Tumor board 25 years of the Endocrine and Surgery collaboration
AACE Thyroid Cancer Tumor board 25 years of the Endocrine and Surgery collaboration Dr. Peter Singer, Endocrinology Dr. Peter Sadow, Pathology Moderator Dr. Greg Randolph, Otolaryngology Relevant Financial
More informationMolecular markers in thyroid cancers
Review Article DOI: 10.18203/issn.2456-3994.IntJMolImmunoOncol20172639 Molecular markers in thyroid cancers Alpa Nimesh Patel, Siddharth Singh Department of Internal Medicine, Pramukhswami Medical College,
More informationMTP: Thyroid Nodules
Canadian Endocrine Update MTP: Thyroid Nodules Deric Morrison MD, FRCP, ECNU Assistant Professor, Division of Endocrinology and Metabolism, Western University April 2014 Faculty/Presenter Disclosure Faculty:
More informationThyroid Pathology: It starts and ends with the gross. Causes of Thyrophobia. Agenda. Diagnostic ambiguity. Treatment/prognosis disconnect
Thyroid Pathology: It starts and ends with the gross Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University of Arkansas for
More informationThyroid Cytology Diagnostic Challenges and Controversies
Thyroid Cytology Diagnostic Challenges and Controversies Tarik M. Elsheikh, MD Professor and Medical Director Anatomic Pathology Cleveland Clinic Outline Thyroid Cytology I and II Introduction The Bethesda
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationThyroid Update. Timothy C. Petersen, MD, ECNU
Thyroid Update Timothy C. Petersen, MD, ECNU TPMG Coastal Endocrinology Virginia Beach, VA About Me Board Certified Endocrinology, Diabetes, and Metabolism Internal Medicine ECNU Certified Endocrine Certification
More informationASCP Competency Assessment
ASCP Competency Assessment Thyroid Cytopathology Ricardo R. Lastra, MD Michelle R. Pramick, MD Zubair W. Baloch, MD, PhD Department of Pathology & Laboratory Medicine University of Pennsylvania, Perelman
More informationWhat s an NIFTP? Keeping Up To Date in Thyroid 2018
What s an NIFTP? Keeping Up To Date in Thyroid 2018 Kathleen Hands, MD, FACE, ECNU Director, Thyroid Center of South Texas Assistant Clinical Professor UTHSCSA DrHands@Thyroid-Center.com 210-844-6163 text
More informationThe Bethesda system for reporting thyroid cytopathology: Should Sri Lanka adopt it?
The Bethesda system for reporting thyroid cytopathology: Should Sri Lanka adopt it? Professor. Chandu de Silva Chair and Senior Professor of Pathology Department of Pathology, Faculty of Medicine, University
More informationCase year female. Routine Pap smear
Case 1 57 year female Routine Pap smear Diagnosis? 1. Atypical glandular cells of unknown significance (AGUS) 2. Endocervical AIS 3. Endocervical adenocarcinoma 4. Endometrial adenocarcinoma 5. Adenocarcinoma
More informationMedical Policy Manual. Topic: Molecular Markers in Fine Needle Aspirates of the Thyroid. Date of Origin: April 2013
Medical Policy Manual Topic: Molecular Markers in Fine Needle Aspirates of the Thyroid Date of Origin: April 2013 Section: Genetic Testing Last Reviewed Date: April 2014 Policy No: 49 Effective Date: July
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid
Molecular Markers in Fine Needle Aspirates of the Thyroid Policy Number: 2.04.78 Last Review: 3/2014 Origination: 3/2013 Next Review: 3/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationClinical and Molecular Approach to Using Thyroid Needle Biopsy for Nodular Disease
Clinical and Molecular Approach to Using Thyroid Needle Biopsy for Nodular Disease Robert L. Ferris, MD, PhD Department of Otolaryngology/Head and Neck Surgery and Yuri E. Nikiforov, MD, PhD Division of
More informationCytological Evaluation of Thyroid Lesions Based on the Bethesda System.
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-086.Volume 5, Issue 2 Ver. VII (December. 206), PP 2-7 www.iosrjournals.org Cytological Evaluation of Thyroid Lesions
More informationAACE-AME 2016 Thyroid Nodule Update
AACE-AME 2016 Thyroid Nodule Update 26 th Annual AACE Meeting & Clinical Congress Austin May 1-5, 2017 Hossein Gharib, MD, MACP, MACE Professor, Mayo Clinic College of Medicine Past President, American
More informationThyroid nodules - medical and surgical management. Endocrinology and Endocrine Surgery Manchester Royal Infirmary
Thyroid nodules - medical and surgical management JRE Davis NR Parrott Endocrinology and Endocrine Surgery Manchester Royal Infirmary Thyroid nodules - prevalence Thyroid nodules common, increase with
More informationPredictors of Malignancy in Thyroid Fine-Needle Aspirates Cyst Fluid Only Cases
Predictors of Malignancy in Thyroid Fine-Needle Aspirates Cyst Fluid Only Cases Can Potential Clues of Malignancy Be Identified? Mohammad Jaragh, MD 1 ; V. Bessie Carydis, MMedSci (Cytol) 1 ; Christina
More information